About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, February 23rd, 2018

The QualityStocks
Daily Stock List


BioHiTech Global, Inc. (BHTG)

Zacks, MarketWatch, and TradingView reported on BioHiTech Global, Inc. (BHTG), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

BioHiTech Global, Inc. is a green technology business headquartered in Chestnut Ridge, New York. The Company provides unique data-driven solutions for food waste disposal. It develops and deploys innovative and disruptive waste management technologies. BioHiTech Global is a leader in zero waste solutions for businesses and municipalities of all sizes. The Company’s shares trade on the OTC Markets Group’s OTCQB.

BioHiTech Global provides waste management solutions to a global customer base covering a complete set of technology-based disposal options that can have a significant impact on waste generation. This is while providing a true zero landfill environment.

BioHiTech Global has launched its BioHiTech Alto™. This is a next generation interactive industrial communication technology. It permits users to communicate intelligently with industrial equipment in real-time. BioHiTech Alto is an important new element of the Company’s complete food waste solution that uses data and analytics to help drive smarter business decisions.

Moreover, the Company collaborated with Natural Systems Utilities to convert commercial food waste to energy. Furthermore, it launched BioHiTech Cirrus. This is a mobile application (app) for consummate insight into the waste stream.

In 2016, BioHiTech Global expanded its waste stream product offering with the launch of Entsorga North America. The Entsorga North America undertaking expands the Company’s product offering towards providing disruptive, clean technology solutions that progress the international movement towards sustainability and zero waste initiatives.

Entsorga North America will manage Apple Valley Waste Conversions LLC, which is an Entsorga North America part-owned subsidiary, the company that holds an exclusive license to deploy the proprietary Entstorga HEBioT Mechanical Biological Treatment (MBT) technology across the northeastern U.S. The HEBioT MBT system converts food waste, plastics, and other carbon-based materials from the mixed municipal solid waste (MSW) stream into an Environmental Protection Agency (EPA) recognized alternative fuel source. The proprietary HEBioT process recovers close to 80 percent of municipal solid waste.

This past November, BioHiTech Global announced that it completed the acquisition of its first HEBioT renewable waste facility license from Ensorgafin S.P.A (Entsorga) in exchange for a combination of roughly 1,036,000 shares of BioHiTech common stock and $838,000 in cash to be paid through March 31, 2018. The Company controls the exclusive U.S. development rights for Entsorga's patented HEBioT solid waste processing technology in 11 north-eastern States and also the District of Columbia.

Recently, BioHiTech Global announced that a top restaurant and nightlife company with numerous venues in the U.S., has deployed BioHiTech's sustainable food waste disposal solution in seven of its New York City venues. The design of BioHiTech Global's Revolution Series Digesters are to cost effectively meet the needs of the restaurant market segment and many other small volume food waste generators by way of its regulatory compliant digestive technologies.

BioHiTech Global has partnered with Kinderhook Industries. Kinderhook is a private investment firm. It manages greater than $2 billion of committed capital. BioHiTech Global has partnered with Kinderhook to create a "next generation" environmental services platform enterprise.

The two companies, via a series of transactions, completed the acquisition of Gold Medal Services, LLC, a market leader in municipal, commercial, and industrial solid waste collection in the Philadelphia and Southern New Jersey markets as a wholly-owned subsidiary of Gold Medal Group, LLC, a newly created company majority owned by Kinderhook.

BioHiTech Global acquired a 9.2 percent interest in Gold Medal in exchange for 500,000 shares of common stock. In addition, the Company has an option to acquire an additional $5M interest in Gold Medal over the next year.

BioHiTech Global, Inc. (BHTG), closed Friday's trading session at $4.26, down 1.16%, on 4,130 volume with 15 trades. The average volume for the last 60 days is 11,933 and the stock's 52-week low/high is $2.50/$9.50.

Towerstream Corp. (TWER)

ChartPoppers, BUYINS.NET, Damn Good Penny Picks, Penny Stock Prodigy, CoolPennyStocks, Epic Stock Picks, Hit and Run Candle Sticks, HotOTC, MadPennyStocks, MarketClub Analysis, Money Morning, OTCBB Journal, OTCMagic, Penny Picks, Investing Futures, MicroCapDaily, Investment Contrarians, Jason Bond, KingPennyStocks, Broad Street, BullRally, PennyInvest, and PennyOmega reported on Towerstream Corp. (TWER), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Towerstream Corp. is a foremost Fixed-Wireless Fiber Alternative company based in Middletown, Rhode Island. The Company delivers high-speed Internet access to businesses. Together with its subsidiaries, Towerstream provides fixed wireless broadband services and delivers access over a wireless network transmitting over regulated and unregulated radio spectrum to commercial customers in the United States.

Towerstream is a last-mile facilities-based provider. The Company owns its entire network. Towerstream completely bypasses the local exchange carrier and cable providers. Towerstream’s solution to businesses either complements or replaces existing Internet connections.

The Company provides broadband services in twelve urban markets. These include New York City, Boston, Los Angeles, Chicago, Philadelphia, the San Francisco Bay area, Miami, Seattle, Dallas-Fort Worth, Houston, Las Vegas-Reno, and the greater Providence area.

The Company has built 175 Major Points of Presence (POPs). It positions its POPs on the tops of buildings. These include the Empire State Building and Met Life in New York, New York; the Hancock Building in Chicago, Illinois; and the AON Building in Los Angeles, California.

Towerstream provides property managers, building owners, and their commercial tenants a redundant and reliable dense urban network. This network directly connects to the Company’s fiber backbone.

Towerstream has its Single Tenant Internet Solution. This solution is for customers not in On-Net buildings. The Single Tenant Internet Solution provides primary and back-up dedicated internet access as a speedier and less costly alternative to fiber.

The Company chooses the qualified commercial buildings in its markets to be able to provide high-capacity bandwidth at substantial savings. Towerstream’s aim is to highly penetrate each On-Net Building.

Towerstream’s On-Net Service provides businesses within its continually growing portfolio of On-Net buildings with dedicated and symmetrical Internet connectivity. On-Net refers to the extensive number of buildings in the Company’s 12 coverage markets now lit for On-Net Business Internet Service.

This past November, Towerstream announced financial results for Q3 ended September 30, 2017. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $340,000 grew 38 percent in Q3 of 2017 versus Q2 of 2017.

Q3 Revenues of $6,555,000 grew sequentially quarter over quarter. Average Revenue per User (ARPU) for new sales contracts was $579 for Q3 of 2017. This represents a 32 percent increase from Q3 of 2016. Churn (the monthly percent of revenue lost from customers terminating their service) was reduced to 1.26 percent in Q3 of 2017 from 2.02 percent in Q3 of 2016.

Towerstream Corp. (TWER), closed Friday's trading session at $3.49, up 29.74%, on 4,623 volume with 17 trades. The average volume for the last 60 days is 1,558 and the stock's 52-week low/high is $0.0645/$6.50.

Cocrystal Pharma, Inc. (COCP)

Wall Street Resources, Microcapmillionaires, Promotion Stock Secrets, and PennyStocks Forever reported on Cocrystal Pharma, Inc. (COCP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Cocrystal Pharma, Inc. develops novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company utilizes innovative technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The design of these technologies, including its nucleoside chemistry expertise and market-centered approach to drug discovery, are to efficiently deliver small molecule therapeutics, which are safe, effective, and convenient to administer. A biotechnology company, Cocrystal Pharma has offices in Tucker, Georgia and Bothell, Washington.

The Company’s proprietary technologies revolve around a structure-based drug discovery strategy teamed up with extensive nucleoside experience. Employing techniques called protein cocrystallization and X-ray crystallography, Cocrystal Pharma quickly identifies novel binding sites, identifies critical inhibitor-protein interactions, and optimizes the structure of the inhibitor in a highly rapid iterative fashion.

Cocrystal Pharma has identified promising, preclinical stage antiviral compounds for unmet medical needs. These include hepatitis, influenza, as well as norovirus infections. The Company is developing a series of compounds that are potent non-nucleoside and nucleoside inhibitors of hepatitis C NS5B RNA dependent RNA polymerase, a replication enzyme vital to viral replication and are highly conserved between all hepatitis C genotypes. Consequently, inhibitors of this enzyme are likely to have multi- or pan-genotypic activity.

Furthermore, Cocrystal Pharma is developing compounds that inhibit hepatitis C helicase and NS5A, two enzymes vital for viral replication. Additionally, the Company has identified a picomolar inhibitor of NS5A, another important viral replication protein. Its compounds that target NS5B hepatitis C polymerase, NS5A, and NS3 helicase will undergo development as a combination treatment.

Cocrystal Pharma previously announced the successful completion and positive data from the Phase 1a/1b study for its lead broad spectrum compound, CC-31244, in healthy volunteers and in hepatitis C virus (HCV)-infected individuals. CC-31244 is a broad-spectrum, potent NS5B non-nucleoside inhibitor (NNI) of HCV replication with a high barrier to resistance. There were no dose-limiting adverse events, study discontinuations because of adverse events, or serious adverse events reported.

Cocrystal Pharma announced in September of 2017 that it entered into a research collaboration with HitGen, Ltd., a private biotechnology company and InterX, Inc., a private computer software company, to develop small molecule drug candidates against several undisclosed targets.

Through the collaboration, Cocrystal Pharma, HitGen, and InterX scientists will apply HitGen's DNA-encoded library (DEL) technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs.

The DEL technology enables a large number of compounds to be quickly identified for specific drug targets. Cocrystal Pharma will utilize its industrialized crystallization and co-crystallization technology to determine at near atomic resolution the structures of HitGen's selected library compounds that interact with drug targets. Also, InterX will utilize its advanced proprietary software to design superior drugs from the information provided by Cocrystal Pharma and HitGen.

Cocrystal Pharma, Inc. (COCP), closed Friday's trading session at $4.35, even for the day, on 6,870 volume with 21 trades. The average volume for the last 60 days is 135 and the stock's 52-week low/high is $3.76/$9.60.

Innovus Pharmaceuticals, Inc. (INNV)

1-2-3 Stock Alerts, BUYINS.NET, Promotion Stock Secrets, TopPennyStockMovers, DSR News, Penny Stock Hub, PHUB News, Wall Street Mover, HotTopPennyStocks, StockMarketQuote.us, PennyPickAlerts, Fortune Stock Alerts, Penny Stock Bets, StockMister, SeeThruEquityResearch, Penny Stock Circle, and OTPicks reported earlier on Innovus Pharmaceuticals, Inc. (INNV), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Innovus Pharmaceuticals, Inc. is a developing Over-The-Counter (OTC) consumer goods and specialty pharmaceutical company. It involves in the commercialization, licensing, and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharmaceuticals is based in San Diego, California.

The Company generates revenues from its lead products BTH® Testosterone Booster; BTH® Human Growth Agent; Zestra® for female arousal and EjectDelay® for premature ejaculation. Innovus Pharmaceuticals has plans to enter the oncology supportive care OTC market with an exclusive license to two GRAS (Generally Recognized As Safe by the U.S. FDA)-listed compounds, thymol and carvacrol, for cachexia and muscle growth and repair, from the University of Iowa Research Foundation.

Innovus has an additional five marketed products. These include Sensum+® for the indication of decreased penile sensitivity; Zestra Glide®; Vesele® for promoting sexual health; RecalMax™ for promoting brain and cognitive health; Androferti® (in the U.S. and Canada) to support overall male reproductive health and sperm quality; BTH Vision Formula; BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if the Company’s Abbreviated New Drug Application (ANDA) receives approval by the Food and Drug Administration (FDA).

Innovus Pharmaceuticals has started a pre-clinical and clinical program intended to evaluate the safety and efficacy of the combination of its supplement Vesele® for promoting sexual health with sildenafil indicated for treating erectile dysfunction. Sildenafil in the United States sells under the name Viagra® by Pfizer, Inc.

Vesele® is a proprietary oral formulation of L-Arginine and L-Citrulline with the natural absorption enhancer Bioperine®. Vesele® was formulated to increase blood flow and nitric oxide production.

Innovus launched AllerVarx™ in the U.S. in 2017. AllerVarx™ is a clinically proven supplement, scientifically formulated for the relief of allergy symptoms. AllerVarx™, selling in Europe under the brand name Lertal®, is a product the Company exclusively in-licensed for the U.S. and Canada from NTC s.r.l. - an Italian company.

Recently, Innovus Pharmaceuticals announced the approval of its Natural Health Product (NHP) License in Canada for its Apeaz™ product. Apeaz™ is a drug in the U.S. for arthritis pain relief.

Apeaz™ will either be sold by itself as an NHP in Canada or in the future, potentially sold with Innovus Pharmaceuticals’ supplement, ArthriVarx™, a nutritional supplement designed to promote and maximize joint health, when that product is presented to Health Canada for approval.

This month, Innovus Pharmaceuticals announced that the human clinical trial for the patented formulation in its UriVarx® product for bladder health was published in the peer reviewed journal, BMC Complementary and Alternative Medicine (Schoendorfer et al. BMC Complementary and Alternative Medicine (2018) 18:42).

The team of Dr. Niikee Schoendorfer in Australia in collaboration with Innovus Pharmaceuticals’ UriVarx® licensing partner Seipel Group, Ltd conducted the study. The outcome of the study demonstrated statistical significance and clinical relevance in lessening symptoms of Overactive Bladder (OAB), urinary frequency and/or urgency and incontinence.

Innovus Pharmaceuticals, Inc. (INNV), closed Friday's trading session at $0.1751, down 2.18%, on 1,358,607 volume with 141 trades. The average volume for the last 60 days is 909,651 and the stock's 52-week low/high is $0.078/$0.39.

HCi Viocare (VICA)

CEO.ca, MarketWatch, and Financial Times reported earlier on HCi Viocare (VICA), and we also report on the Company, here at the QualityStocks Daily Newsletter.

HCi Viocare concentrates on the development and marketing of prosthetics and orthotics. The Company has a strong pipeline of near-market to research-stage technologies. Established in 2007, it previously went by the name China Northern Medical Device, Inc. It changed its name to HCi Viocare in March of 2014. HCi Viocare has its executive office in Athens, Greece, and its research and development (R&D) center in Glasgow, Scotland, United Kingdom (UK).

The Company’s business model consists of creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and developing a broad portfolio of proprietary hardware solutions with first in line the Flexisense™ sensor system. The clinics will operate according to British and International standards. They will provide independent and personalized quality of care for its patients. The first HCi Viocare clinic has been operating since September of 2015 in Glasgow.

HCi Viocare has two fully owned subsidiaries. One is HCi Viocare Technologies and the other is HCi Viocare Clinics. HCi Viocare Technologies is developing hardware solutions aiming to empower the user through providing on demand information and enhancing living quality.

The R&D center is working on a large portfolio of progressive, leading-edge, and disruptive technologies in the Digital Health, Prosthetics, and Orthotics, Diabetes, Assistive Devices and Sports & Wellbeing fields. The Company has developed an inventive sensing technology with the brand name Flexisense™.

Flexisense™ technology is the next generation of sensing technologies for wearable devices. Flexisense™ is a unique sensing technology. It measures pressure and shear forces. Furthermore, it provides on demand information wirelessly. Flexisense can be incorporated in a broad spectrum of applications.

HCi Viocare Technologies has developed a new application for its sensing technology Flexisense™, now for automotive tires. Flexisense™ applied to tires can monitor, in real time, tire deformation and actual traction between the tire and the ground. Flexisense™ feeds back information to the vehicle's CPU. This lets the vehicle adjust to changing road and weather conditions. Flexisense™ also significantly increases safety and performance.

Yesterday, HCi Viocare announced that its Management, acknowledging the great advantages of Blockchain technology, decided to develop its own proprietary Blockchain based system for handling the sensitive client records in its Scottish Clinics subsidiary. In addition, this team will develop a proprietary Blockchain based system for handling and storing the data produced from the medical applications of its Flexisense™ technology.

HCi Viocare (VICA), closed Friday's trading session at $0.0499, up 22.49%, on 5,000 volume with 2 trades. The average volume for the last 60 days is 25,315 and the stock's 52-week low/high is $0.03/$0.33.

Drone USA, Inc. (DRUS)

OTC Markets, InvestorsHub, Stock News Now, Stock Daily Review, 4-Traders, and Stockhouse reported on Drone USA, Inc. (DRUS), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Drone USA, Inc. is a developer, manufacturer, and distributor of low altitude drones and related technologies. The Company’s principal target markets include U.S. police, firemen, and the U.S. Government. Drone USA designs and builds high quality drones, training, insurance, replacement parts and anything a customer needs to make sure their missions are successful. All the Company’s products will be manufactured and assembled in the U.S.

Drone USA has its corporate office in West Haven, Connecticut. The Company lists on the OTC Markets’ OTCQB.

The services Drone USA offers include Real Estate Photography for Advertisement; Utility Inspection; and Construction Inspection & Photo/Video Marketing. Moreover, Services include Precision Agriculture; Search & Rescue Assistance; and Fire Hot Spot Location. All of Drone USA’s drones operate with closed encrypted software. This is for national security purposes.

Howco Distributing Co. (Vancouver Washington) is a subsidiary of Drone USA. Howco Distributing is Drone USA’s manufacturing supply chain segment.

Howco Distributing is a premier supplier of spare and replacement parts to the United States Federal Government and commercial customers around the world. Howco is an authorized provider for hundreds of manufacturers and original equipment manufacturers (OEM’s).

Howco Distributing's services cover bid solicitation, contract management, packaging and logistics for construction, transportation, mining and heavy equipment spare and replacement parts to customers globally using a broad array of supply chain solutions.

Drone USA is working on three profitable growth strategies. These are Police & U.S. Government drone sales; growing Howco Distributing’s product line and reach; and acquiring companies that broaden Drone USA’s product and customer base.

In October 2017, Drone USA announced that its Connecticut subsidiary, HowcoCT, officially opened its doors for business in West Haven, Connecticut.

Mr. Michael Bannon, Chief Executive Officer of Drone USA, said, “Part of our three-pronged approach to profitable growth is opening other Howco Distributing locations throughout the United States. A core component to our competitive advantage stems from being near our suppliers. We have identified several existing Howco suppliers in the Northeast region.”

This past December, Drone USA announced the sale of 15 surveillance drones. This sale was to a $120-billion Fortune 500 company.

Drone USA, Inc. (DRUS), closed Friday's trading session at $0.0904, up 6.35%, on 106,380 volume with 16 trades. The average volume for the last 60 days is 16,159 and the stock's 52-week low/high is $0.085/$0.40.

LexaGene Holdings, Inc. (LXXGF)

MarketWatch, Stockhouse, Capital Cube, Barchart, Pinnacle Digest, Stockwatch, YCharts, MetalsNews.com, The Street, OTC Markets, Dividend Investor, Insider Financial, Investor Place, Financial Trends, and Markets Insider reported on LexaGene Holdings, Inc. (LXXGF), and today we choose to report on the Company as well, here at the QualityStocks Daily Newsletter.

A biotechnology company listed on the OTCQB, LexaGene Holdings, Inc. develops instrumentation for pathogen detection. It is developing the LX6, which is the very first fully automated pathogen detection platform that is open-access. This open-access feature will enable end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection. LexaGene Holdings has its corporate headquarters in Beverly, Massachusetts.

Earlier this month, LexaGene announced that it considerably expanded its operations in Massachusetts. The Company recently signed a lease for a 17,500-square-foot space, located at 500 Cummings Center, Suite 4550, in Beverly.

LexaGene Holdings is working to change the pathogen detection landscape through providing a customizable sample-to-answer instrument, which is more rapid and sensitive than anything presently available. It is working to transform the way pathogen testing is performed by multi-billion dollar industries. These industries include food safety, veterinary diagnostics, water quality management, aquaculture farming, and more.

LexaGene Holdings has strategic relationships with Boston Engineering – a development partner; as well as the Lawrence Livermore National Laboratory. The Company’s Microfluidic Technology is open access - users can load standard pathogen specific assays onto the instrument for customized testing.

A feature of this technology is extreme sensitivity. The flow-through instrument processes huge sample volumes to maximize the chances of detecting ultra-rare pathogens. The Microfluidic Technology features low cost per test and it is also user-friendly.

At the end of November 2017, LexaGene announced that it completed the assembly of its prototype for what will be the world’s first fully automated, open-access and on-site pathogen detection platform. This technology will be able to screen for up to 22 pathogens at once and deliver results in one hour. The design of the technology is also to be used by people with no knowledge of automated instrumentation, microbiology, or molecular biology.

Yesterday, LexaGene Holdings announced that the TSX Venture Exchange ranked the Company in its 2018 TSX Venture 50. This is a yearly ranking of top performing companies on the Exchange.

Dr. Jack Regan, LexaGene Holdings’ Chief Executive Officer, said, “Being recognized as a top 50 company for the Exchange reflects the rapid growth we’ve experienced in 2017 and great support from the investment community. Following our recent completion of the assembly of our prototype for what will be the world’s first fully automated, open-access and on-site pathogen detection platform, LexaGene is poised to make a powerful impact for industries interested in pathogen detection – from food safety to veterinary diagnostics.”

LexaGene Holdings, Inc. (LXXGF), closed Friday's trading session at $1.13, up 4.65%, on 109,830 volume with 74 trades. The average volume for the last 60 days is 70,677 and the stock's 52-week low/high is $0.3978/$1.285.

Blow & Drive Interlock Corp. (BDIC)

TradingView, Equities.com, MarketWatch, YCharts, and News to Watch reported on Blow & Drive Interlock Corp. (BDIC), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Blow & Drive Interlock Corp. provides automotive and criminal offender monitoring security products. The Company has its state‐of‐the‐art ignition interlock device: BDI-747. This device is approved and available in eight states for evidentiary and preliminary screening use. Fundamentally, Blow & Drive Interlock is an offender monitoring and police-grade alcohol detection device manufacturing and offender monitoring business.

The Company lists on OTC Markets Group’s OTCQB. Blow & Drive Interlock is headquartered in Los Angeles, California.

Interlocks are required for use by DUI or DWI (Driving Under The Influence or Driving While Intoxicated) offenders. This is as part of their mandatory court or motor vehicle department program.

Blow & Drive Interlock’s goal is to have the BDI-747 available to customers across the United States. Furthermore, the Company continues to do research and development (R&D) on the next stage of offender monitoring. It believes this will be Smartphone enabled monitoring applications (apps) that could decrease or eliminate the need for ankle bracelets or hand-held breathalyzers.

Blow & Drive Interlock’s BDI-747 is an ignition interlock device, breath-alcohol testing device roughly the size of a Smartphone. The ignition interlock device requires the driver to exhale into the device before starting the vehicle. The device will prevent the vehicle from starting if the driver's blood-alcohol content surpasses a predetermined set level.

The BDI-747 can record BAC levels. It provides 2-way communication, GPS location technology, and image technology. In addition, the BDI-747 is wireless.

At the beginning of November, Blow & Drive Interlock announced its newest products to go to market in Early 2018. The Company unveiled and demonstrated its Home Alcohol Monitoring Device.

The Handheld device has a camera and GPS/WIFI & live streaming. It allows those in Judicial and Probation departments to monitor offenders who are required to stay sober from alcohol while on probation.

Blow & Drive Interlock also unveiled its 4G LTE Live-Streaming Video Body Worn Camera for Law Enforcement. With the Company’s 4G LTE Live-Streaming Video Body Worn Camera, Law Enforcement Personnel on the scene can transmit a live feed from their body cameras to headquarters. This permits police decision makers’ access to real time information concerning what each officer is seeing.

The body camera weighs approximately 210g. It provides up to 32 GB of memory and 5-megapixel recording. Moreover, it offers infrared technology for night recording, numerous resolution settings, pre-and post-recording capabilities, and many more features. These are to assist officers in obtaining high quality video recording.

Blow & Drive Interlock Corp. (BDIC), closed Friday's trading session at $0.1969, up 15.82%, on 5,231 volume with 2 trades. The average volume for the last 60 days is 5,274 and the stock's 52-week low/high is $0.1381/$0.52.

SANUWAVE Health, Inc. (SNWV)

Greenbackers, OTCJournal, FeedBlitz, AllPennyStocks, OTC Stock Review, Explicit Penny Picks, Free Investment Report, Free Penny Alerts, Gladiator Stocks, InsidersLab, KillerPennyStocks, Marketbeat.com, RedChip, TopPennyStockMover, SmallCapVoice, PennyStocks24, OTC Stock Review, Penny Stock Rumble, Streetwise Reports, The Green Baron, and Ox of Wallstreet reported on SANUWAVE Health, Inc. (SNWV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets’ OTCQB, SANUWAVE Health, Inc. is a shock wave technology business. The Company’s initial concentration is on the development and commercialization of patented non-invasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, as well as vascular structures. SANUWAVE Health researches, designs, and manufactures, markets and services its products around the world. SANUWAVE Health is based in Suwanee, Georgia.

The Company’s lead product candidate for the international wound care market, dermaPACE®, is CE marked across Europe. It has Canada, Australia, and New Zealand device license approval for the treatment of skin and subcutaneous soft tissue.

Last month, SANUWAVE Health announced that the U.S. Food and Drug Administration (FDA) issued its decision on the de novo submission for the dermaPACE® System. Their decision (dated December 28, 2017) permits the marketing of the dermaPACE System as a Class II medical device used for the treatment of Diabetic Foot Ulcers (DFU) in the United States.

SANUWAVE applies its patented Pulsed Acoustic Cellular Expression (PACE®) technology in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions. The Company’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses. This produces new vascularization and microcirculatory improvement. This helps in restoring the body's normal healing processes and leads to regeneration of tissue.

The Company’s belief is that it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, and also stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment via the use of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific.

In addition, there are license/partnership opportunities for SANUWAVE Health’s shock wave technology for non-medical uses. This includes energy, water, food, and industrial markets.

This month, SANUWAVE Health announced a partnership agreement was reached with Premier Shockwave Wound Care, Inc. and Premier Shockwave, Inc. (collectively Premier). This agreement will cover the Veteran’s Administration (VA), Indian Health Service (IHS) and Tribally operated healthcare services, and US Military facilities/bases (MTFs).

With this agreement, Premier will purchase an undisclosed number of dermaPACE units to service these end markets. SANUWAVE Health will receive revenue from the sale of the equipment and a per procedure fee from Premier. This contract includes a minimum purchase of 100 units over three years.

The expectation is that the contract will provide a high margin, recurring revenue as Premier rolls out its services. The agreement allows SANUWAVE to enter the market immediately, thus speeding up revenue growth by years.

SANUWAVE Health, Inc. (SNWV), closed Friday's trading session at $0.325, up 8.33%, on 640,671 volume with 141 trades. The average volume for the last 60 days is 374,803 and the stock's 52-week low/high is $0.081/$0.30.

Bone Biologics Corporation (BBLG)

OTC Markets, MarketWatch, Investing.com, 4-Traders, BusinessWire, Simply Wall St, YCharts, The Street, GuruFocus, StreetInsider, Market Exclusive, and MarketsandMarkets reported on Bone Biologics Corporation (BBLG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bone Biologics Corporation concentrates on developing and marketing orthobiologic products. The Company’s proprietary platform technology is NELL-1. This is a recombinant human protein growth factor essential for normal bone development. At present, Bone Biologics is focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion. OTCQB-listed, the Company is headquartered in Burlington, Massachusetts.

Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering founded Bone Biologics in 2004.

Bone Biologics’ corporate mission is to use the power of NELL-1 to improve clinical outcomes and lessen total health care delivery costs associated with spinal fusion. The Company’s lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the fast growing orthobiologics market. NELL-1 provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as demonstrated in the lab and via the use of animal testing.

NELL-1 is a recombinant human protein growth factor. It has the same functionality as the endogenous NELL that is essential for normal bone development. Bone Biologics’ dedication is to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the present options provide suboptimal patient outcomes.

In August of 2017, Bone Biologics announced that it expanded its Field of Use definition of the license agreement with the UCLA Technology Development Group on behalf of UC Regents for NELL-1. In addition, the Company entered into an exclusive license agreement with the UCLA Technology Development Group on behalf of UC Regents for the global application of the NELL-1 protein for osteoporosis and trauma by way of a technology transfer.

This past December, Bone Biologics announced that it completed a preclinical study that shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. Furthermore, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.

Mr. Steve La Neve, Bone Biologics’ Chief Executive Officer, said, “We are very encouraged by the results of our Pilot animal study and look forward to commencing our Pivotal animal study by mid-2018 and presenting results at future scientific conferences.”

Bone Biologics Corporation (BBLG), closed Friday's trading session at $1.131, down 1.99%, on 100 volume with 1 trade. The average volume for the last 60 days is 1,863 and the stock's 52-week low/high is $0.51/$5.90.


The QualityStocks
Company Corner


Reign Sapphire Corp. (RGNP)

The QualityStocks Daily Newsletter would like to spotlight Reign Sapphire Corp. (RGNP). Today, Reign Sapphire Corp. closed trading at $0.16, up 14.29%, on 149,609 volume with 28 trades. The stock’s average daily volume over the past 60 days is 54,881, and its 52-week low/high is $0.0519/$0.325.

Consumer awareness and Congressional legislation have fueled a growing focus on the ‘ethical’ production of minerals for everything from jewelry to electronics in the years since, and Reign Sapphire Corp. (OTCQB: RGNP) has established such a standard of care in its global direct-to-consumer brand of custom jewelry.

Reign Sapphire Corp. (RGNP), is a direct-to-consumer, custom and branded jewelry company headquartered in Los Angeles, California. Reign's mission is to provide ethical and sustainable jewelry direct to the modern consumer, marketed through sophisticated digital initiatives that speak directly to individuals through social media channels and personalized promotions. The company's lean operating model ensures expenses are linked to order flow with flexible production schedules targeting just-in-time delivery, which in turn reduces or eliminates commodity risk. Reign is a member of the American Gem Trading Association, which is committed to fair trade and processing of gemstones.

Reign Sapphire Corp. owns and operates three divisions: Reign Brands, Reign Ventures and Reign Blockchain. Reign Brands features four unique, niche jewelry brands with separate social media followings:

  • Reign Sapphires: Ethically produced, millennial-targeted sapphire jewelry sourced from Australia.
  • Coordinates Collection: Custom jewelry inscribed with location coordinates commemorating life's special moments.
  • Le Bloc: Classic, customized jewelry.
  • ION Collection by Jen Selter: Athleisure jewelry brand.

Reign Ventures is the company's joint venture platform for investment and development of jewelry technology-related products.

Reign Blockchain authenticates its sapphires as conflict-free, allowing customers to wear products created by a company that shares their beliefs in human dignity and environmental stewardship. In 2018, Reign Blockchain is preparing to conduct an initial coin offering (ICO) for ReignCoin, subject to regulatory approval. ReignCoin will serve as Reign's cryptocurrency as part of a blockchain-based loyalty reward program.

The company's products are sold through a commission-based affiliate program that is supported by personalized email campaigns and promotions, celebrity promotion and gifting, digital advertising based on keyword purchases and sponsored ads, and creative publicity events and media outreach to attract maximum exposure. The successful launch of a company-wide social media influencer campaign across all its retail brands boosted Reign's Instagram, Twitter and Facebook followings by double digits within the first three weeks of going live.

Reign continues to seek out international partnerships, adding to the success it has already achieved in the Middle East, where its flagship store is in the Dubai Mall. The company recently teamed up with the original founder of its Coordinates Collection brand, Owen de Vries, who will lead its Europe and United Kingdom sales efforts. The Netherlands-based operation will proliferate Reign point-of-sales that are adapted for local language, digital marketing and customer service.

Reign Sapphire Corp. is led by president and CEO Joseph Segelman, who has also served on the board of directors since December 2014. Segelman earlier served as the Chief Executive Officer and managing director of Australian Sapphire Corporation, Shefa Mining Corporation and Spencer Lloyd & Associates. He is an experienced marketing and operations professional with over 20 years of experience in logistics and marketing, and extensive experience in the Australian mining and gem industry. He is also a director and board member of OBK (a Sydney, Australia, based charity) and a Captain (Chaplain) in the Australian Army reserves. Segelman is the author of "Take Action: Successful Australians Share their Secrets." (Lothian Books, 2004).

The company's board of advisors includes Andrea Hansen, jewelry marketing veteran and former president of the Women's Jewelry Association; Jeremy Avitan, CPA and compliance executive; Michael Lawrence corporate lawyer and litigator, Doug Cole, corporate financier and entrepreneur, Thierry Chaunu, a luxury goods executive with prior senior management roles at Chopard, Christofle and Cartier, and Pinny Gwinisch, founder of Ice.com and adjunct professor at McGill and Rutgers University. Disclaimer

Reign Sapphire Corp. Company Blog

Reign Sapphire Corp. News:

Reign Sapphire Corp. (RGNP) Delivers Conflict-Free Gems Directly to Consumers

Reign Sapphire Corp. and StarShop Sign Marketing Agreement to Promote Top Social Media Influencer Brand

NetworkNewsBreaks – Why Reign Sapphire Corp. (RGNP) is “One to Watch”

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $1.2556, up 3.79%, on 132,940 volume with 129 trades. The stock’s average daily volume over the past 60 days is 288,922 and its 52-week low/high is $0.543/$1.5835.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTC:MGXMF) is pleased to announce the Company has chosen to proceed with its previously announced partnership with Highbury Energy Inc. (“Highbury”) to develop a detailed thermochemical gasification process to extract metals such as nickel, vanadium, cobalt and hydrogen from petroleum coke (“Petcoke”).

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals to Proceed with Hydrogen Gasification and Battery Metals Extraction from Petroleum Coke; Receives Initial Vanadium Nickel Cobalt Assay Results

MGX Minerals Announces Completion of 3,000 Metre Drill Program at Case Lake Lithium; 8,000 Metre Spring Drill Program Planned

MGX Minerals Commences Lithium Brine Testing in Chile; Multiple Projects to be Evaluated

AnalytixInsight Inc. (TSX.V:ALY) (OTCQB:ATIXF)

The QualityStocks Daily Newsletter would like to spotlight AnalytixInsight Inc. (ATIXF). Today, AnalytixInsight Inc. closed trading at $0.3805, up 3.71%, on 6,900 volume with 6 trades. The stock’s average daily volume over the past 60 days is 35,614 and its 52-week low/high is $0.15/$0.6898.

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) plans to integrate its 49 percent-owned fintech subsidiary’s real-time stock trading app, Marketwall, into Italy-based banking group Intesa Sanpaolo during 2018. This will give ATIXF exposure to the group’s eight million stock-trading clients (http://nnw.fm/uv4Bs). The integration is expected to be available in six countries.

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) is an artificial intelligence (AI) company that transforms data into knowledge. The company has developed a proprietary, machine-learning technology that algorithmically analyzes big data and distills it into actionable insights. AnalytixInsight has strategic initiatives in fintech, blockchain and workflow analytics, and its technology is scalable and extendable to virtually any data-driven industry such as sports, communications, healthcare, insurance or government.

The company's flagship product – CapitalCube.com – is a financial portal providing comprehensive company analysis including on-demand fundamental research, portfolio evaluation and screening tools on over 50,000 global equities and North American ETFs. CapitalCube's online portal is designed to empower investment ideas by providing in-depth analysis, peer-to-peer performance evaluations, accounting and earnings reports, dividend strength and AI-supported information about likely corporate actions such as dividend changes, share buybacks and acquisitions. AnalytixInsight provides a robust technology that is frequently rebalanced to maintain a desired risk profile, matching risk to ideal ETF exposure, with regular compliance reporting.

CapitalCube's freemium pricing model allows free access to basic financial information, with additional in-depth analysis and predictive analytics provided at a rate of $25 per month, and customized peer analysis for $300 per month. CapitalCube publishes 3,000 articles daily and has multi-language capabilities. Thomson Reuters and Africa Investor have recently been added to the growing network of content partnerships that already includes Euronext NV, Yahoo Finance and The Wall Street Journal.

Euclides Technologies is a subsidiary company focused on Field Service Management software solutions, led by a team with decades of experience in developing and implementing workforce management solutions for large global corporations. With worldwide customers representing over 100,000 field service personnel across multiple industries, Euclides Technologies has a deep understanding of the increasing amount of data generated within the industry, as well as the analytics solution offerings to transform that data into knowledge.

MarketWall is a Fintech subsidiary that develops integrated software solutions as part of an ecosystem of smart devices that includes PCs, tablets, smart phones, wearable mobile devices and Smart TV. AnalytixInsight Inc. has joint ownership in MarketWall together with Intesa Sanpaolo, Italy's largest retail bank which has over 4,000 branches and a market capitalization of $40 billion Euros. MarketWall is expected to deploy its real-time stock trading and mobile banking app to Intesa Sanpaolo's 12.6 million customers in six European countries during 2018. The mobile stock trading application will directly interface with Intesa Sanpaolo's established MarketHub trading platform. As a Samsung Global Partner, the MarketWall app is preloaded in mobile devices in certain areas in Europe.

AnalytixInsight is currently evaluating and pursuing Blockchain initiatives which are contiguous with its artificial intelligence platform, to use a distributed ledger technology to reduce transaction costs and settlement times for its users, partners, and subsidiaries. The Company believes these initiatives will enhance current revenues being received from existing multi-year agreements with its partners. Disclaimer

AnalytixInsight Inc. Blog

AnalytixInsight Inc. News:

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) Plans 2018 Rollout of Stock Trading App

AnalytixInsight Named a Top 10 Technology Company on the TSX Venture 50™

NetworkNewsBreaks – AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) Offers In-depth Analysis, Predictive Analytics with CapitalCube Online Portal

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.5742, up 0.74%, on 73,222 volume with 54 trades. The stock’s average daily volume over the past 60 days is 234,493 and its 52-week low/high is $0.22/$0.881.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP) is pleased to announce that it has completed the Share Purchase Agreement (the “Agreement”) with 906474 ALBERTA LTD. (the "Vender") for 100% of Sechelt Organic Marijuana Corp. (“SOM”).

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Pharma Completes Share Purchase Agreement of Sechelt Organic Marijuana Corp.

Veritas Pharma Provides Corporate Update on Q1 2018

Veritas Intends to Complete the 100% Takeover of Cannevert Therapeutics in Q1

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.07, off by 0.57%, on 2,044,518 volume with 256 trades. The stock’s average daily volume over the past 60 days is 12,053,108, and its 52-week low/high is $0.0132/$0.415.

Specialized holding company SinglePoint, Inc. (OTCQB: SING) was a featured company on this week’s episode of MoneyTV with Donald Baillargeon. Also today, NetworkNewsWire released a report looking at blockchain, the technology behind cryptocurrencies such as bitcoin, and how this technology boasts tremendous disruptive potential in a wide range of industries, including finance, infrastructure, supply chain management and even healthcare. The report looks at how SinglePoint, has teamed up with ORHub, Inc. (ORHB) to create a blockchain-based solution to improve the way hospitals collect and utilize operating room data to reduce supply chain costs. Furthermore, we saw the release of the latest key findings by Growth Market Report for all traders, shareholders, and investors of Singlepoint Inc. (OTCQB: SING) and Innovus Pharmaceuticals, Inc. (OTCQB: INNV), including recent technical analysis and consolidated fundamental information.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsBreaks – SinglePoint, Inc. (SING) CEO Discusses Recent LOI, Acquisition Strategy in Interview on MoneyTV

Emerging Developments: Singlepoint and Innovus Pharmaceuticals - A Look Ahead into 2018

Blockchain Innovations Set to Disrupt Healthcare

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $1.14, off by 0.87%, on 45,903 volume with 57 trades. The stock’s average daily volume over the past 60 days is 139,943 and its 52-week low/high is $0.20/$1.75.

NetworkNewsWire released a report today looking at blockchain, the technology behind cryptocurrencies such as bitcoin, and how this technology boasts tremendous disruptive potential in a wide range of industries, including finance, infrastructure, supply chain management and even healthcare. The report looks at how specialized holding company Singlepoint Inc. (OTCQB: SING), has teamed up with ORHub, Inc. (ORHB) to create a blockchain-based solution to improve the way hospitals collect and utilize operating room data to reduce supply chain costs.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

Blockchain Innovations Set to Disrupt Healthcare

SinglePoint Signs LOI with ORHub to Launch Healthcare Blockchain Initiative

ORHub Launches Healthcare Blockchain Initiative to Expand Data Innovation at Point of Care

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.8654, off by 1.35%, on 169,863 volume with 159 trades. The stock’s average daily volume over the past 60 days is 294,722, and its 52-week low/high is $0.3148/$1.3041.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF), a client of NNW focused on creating the largest pure-play cobalt exploration and development company in the world. To view the full publication, titled “Rise of Electric Cars Fuels Cobalt Market Surge,” visit: http://nnw.fm/ewZk1.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

NetworkNewsWire Announces Publication on Cobalt’s Rising Demand to Power Green Cars

NetworkNewsBreaks – First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) Recognized as Top Mining Firm in TSX Venture 50™

Rise of Electric Cars Fuels Cobalt Market Surge

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.024, off by 6.25%, on 11,064,933 volume with 234 trades. The stock’s average daily volume over the past 60 days is 15,725,681, and its 52-week low/high is $0.0141/$0.16.

CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Global Payout, Inc. (GOHE), a client of CNW and a leading provider of comprehensive and customized prepaid payment solutions for domestic and international organizations distributing money worldwide. To view the full publication, titled “The Modern Cannabis Industry — A Tight Mesh of Integrated Verticals and Technologies,” visit: http://nnw.fm/Z5dfE.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

CannabisNewsWire Announces Publication on High-Potential Integrations Forming in Booming Cannabis Industry

Preparing for Growth: MoneyTrac Technology CEO Suspends Salary to Accelerate Expansion in 2018

The Modern Cannabis Industry — A Tight Mesh of Integrated Verticals and Technologies

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.35, off by 7.89%, on 42,673 volume with 23 trades. The stock’s average daily volume over the past 60 days is 13,362, and its 52-week low/high is $0.01/$0.80.

NetworkNewsAudio announces the Audio Press Release (APR) titled "A New Breakthrough in Cannabinoid Drug Delivery," featuring PreveCeutical Medical Inc. (OTCQB: PRVCF) (CSE: PREV) (FSE: 18H). To hear the NetworkNewsAudio version, visit: http://nnw.fm/MAut8. To read the original editorial, visit: http://nnw.fm/fgNH5.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

NetworkNewsAudio Announces Audio Press Release (APR) on PreveCeutical Medical Inc.Transforming Industry with Cannabinoid Delivery Advancements

NetworkNewsWire Announces Publication on Unique New Paradigms in Cannabinoid Drug Delivery

A New Breakthrough in Cannabinoid Drug Delivery

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.002, even with yesterday's close. The stock’s average daily volume over the past 60 days is 235,396, and its 52-week low/high is $0.0005/$0.008.

Consorteum Holdings, Inc. (CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company's commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ ("UMI") solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company's UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum's wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company's UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI's technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum's primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum's management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum's management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

NetworkNewsBreaks – Consorteum Holdings, Inc. (CSRH) Extends Agreement, Combines Strengths with Knockout Gaming, Inc.

Consorteum Holdings, Inc. (CSRH) Extends Strategic Agreement with Knockout Gaming, Inc.

NetworkNewsBreaks – Why Consorteum Holdings, Inc. (CSRH) is “One to Watch”


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(VICR) +37.23%


(ORSX) +34.17%


(ZMD) +33.33%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251